HCPLive 5 Stories in Under 5: Week of 02/01

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for February 1-7, 2026:1. FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic ReactionsThe FDA issued a Complete Response Letter for sublingual dibutepinephrine after identifying human factors issues that could compromise safe use during anaphylaxis, underscoring the importance of reliable administration in emergency settings.2. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic DermatitisPhase 2 data indicate roflumilast cream was well tolerated in infants with atopic dermatitis and showed early signs of clinical improvement, supporting potential expansion of topical PDE4 inhibition into this very young population.3. FDA Accepts Resubmitted BLA for RelabotulinumtoxinA for Glabellar and Lateral Canthal LinesThe FDA accepted Galderma’s resubmitted BLA for relabotulinumtoxinA following manufacturing process updates, allowing regulatory review to resume for treatment of glabellar and lateral canthal lines.4. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with VitiligoAbbVie submitted regulatory applications seeking to expand upadacitinib use to adults and adolescents with non-segmental vitiligo, positioning a systemic JAK inhibitor as a potential option for this underserved condition.5. VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2DPositive phase 2b results suggest Pfizer’s long-acting GLP-1 receptor agonist may support sustained weight management with extended dosing intervals in patients without diabetes.